Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $30 from $20 and keeps an Outperform rating on the shares. The firm cites a “meaningful increase” in its peak-year global end-user sales estimate for the company’s lead asset soquelitinib in atopic dermatitis for the target bump. The recent weakness in the stock provides an opportunity to add to positions, the analyst tells investors in a research note.